Home » Local, Technology

Boston Scientific Very Promising New Defibrillator Statistics (BSX)

Submitted by on June 23, 2009 – 3:50 PM
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading ... Loading ...
Print This Post Print This Post | No Comment

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

Boston Scientific Corporation (NYSE: BSX) has been down and almost out for almost as long as memory serves.  The company can’t even blame a bear market for its share price woes.  But the company has some solid news in its cardiac resynchronization therapy defibrillators showing a great reduction in death.  If this holds up, it could be one of the best things for the company in recent periods.

The company and the University of Rochester Medical Center have announced that the landmark MADIT-CRT trial has met its primary endpoint, where the preliminary results showed the cardiac resynchronization therapy defibrillators with a significant 29% reduction in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators.

Read the full story »

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.